Ainos (AIMD) 10-K 17 Apr 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Apr. 14, 2017
Document Information [Line Items]
Entity Registrant Name	AMARILLO BIOSCIENCES INC
Entity Central Index Key	1,014,763
Trading Symbol	amar
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		22,350,935
Entity Public Float	$ 3,502,620
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	$ 134,125	$ 21,138
Inventory	14,700	0
Advance to related party	37,835
Prepaid expense and other current assets	75,739	18,154
Total current assets	262,399	39,292
Patents, net	156,063	72,105
Property and equipment, net	44,214	5,798
Total assets	462,676	117,195
Liabilities and Stockholders' Deficit
Accounts payable and accrued expenses	165,502	58,550
Accrued interest - related parties	3,259	1,706
Accounts payable – related parties		144,426
Advance from related party	187,500
Customer deposits – related party	124,833
Notes payable – related parties		384,555
Convertible note payable – related party	791,481
Total current liabilities	1,272,575	589,237
Total liabilities	1,272,575	589,237
Commitments and contingencies
Stockholders' deficit
Preferred stock, $0.01 par value: Authorized shares - 10,000,000, Issued and outstanding shares – 0 at December 31, 2016 and December 31, 2015
Common stock, $0.01 par value: Authorized shares - 100,000,000, Issued and outstanding shares – 21,916,143 and 20,144,810 at December 31, 2016 and 2015, respectively	219,161	201,448
Additional paid-in capital	237,540	(76,872)
Accumulated deficit	(1,266,600)	(596,618)
Total stockholders' deficit	(809,899)	(472,042)
Total liabilities and stockholders’ deficit	$ 462,676	$ 117,195

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common Stock, Shares Authorized	100,000,000	100,000,000
Common stock, shares issued (in shares)	21,916,143	20,144,810
Common Stock, Shares, Outstanding	21,916,143	20,144,810

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenues
Cost of revenues
Gross margin (loss)
Operating expenses:
Research and development expenses
Selling, general and administrative expenses	667,111	519,821
Total operating expenses	667,111	519,821
Operating loss	(667,111)	(519,821)
Other income (expense):
Interest expense	(2,871)	(2,053)
Net loss	$ (669,982)	$ (521,874)
Basic and diluted net loss per average share available to common shareholders (in dollars per share)	$ (0.03)	$ (0.03)
Weighted average common shares outstanding – basic and diluted (in shares)	21,055,886	20,144,810

Statements of Stockholders' Def

Statements of Stockholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2014		20,144,810
Balance at Dec. 31, 2014		$ 201,448	$ (157,446)	$ (74,744)	$ (30,742)
Cash received from stock subscription			80,574		80,574
Net loss				(521,874)	(521,874)
Balance (in shares) at Dec. 31, 2015		20,144,810
Balance at Dec. 31, 2015		$ 201,448	(76,872)	(596,618)	(472,042)
Net loss				(669,982)	(669,982)
Balance (in shares) at Dec. 31, 2016		21,916,143
Balance at Dec. 31, 2016		$ 219,161	237,540	(1,266,600)	(809,899)
Issuance of stock for cash in private placements (in shares)		1,771,333
Issuance of stock for cash in private placements		$ 17,713	$ 314,412		$ 332,125

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from Operating Activities
Net loss	$ (669,982)	$ (521,874)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	25,956	19,772
Changes in operating assets and liabilities:
Inventory	(14,700)
Prepaid expense and other current assets	(95,420)	(1,272)
Accounts payable and accrued expenses	106,952	(8,609)
Accrued interest – related parties	1,553	1,143
Accounts payable – related party		144,426
Customer deposits	124,833
Net cash used in operating activities	(520,808)	(366,414)
Cash flows from Investing Activities
Investment in patents	(100,644)	(4,497)
Capital expenditures	(47,686)	(7,081)
Net cash used in investing activities	(148,330)	(11,578)
Cash flows from Financing Activities
Cash received from stock subscription		80,574
Proceeds from private placement offering	332,125
Advance from related party	187,500
Proceeds from convertible note payable - related party	262,500
Net cash provided by financing activities	782,125	80,574
Net change in cash	112,987	(297,418)
Cash and cash equivalents at beginning of period	21,138	318,556
Cash and cash equivalents at end of period	134,125	21,138
Supplemental Cash Flow Information
Cash paid for interest	1,318	910
Cash paid for income taxes
Non-Cash Transactions
Conversion of accounts payable - related party to convertible note payable – related party	144,426
Conversion of notes payable - related party to convertible note payable – related party	$ 384,555

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Business Amarillo Biosciences, Inc. (the "Company” or “ABI”), a Texas corporation formed in 1984, The Medical Division is preparing to deploy diabetic treatment centers in Taiwan beginning sometime in the third 2017. 1 2 Going Concern These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved operating income, and its operations are funded primarily from debt and equity financings. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability. The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may may may Fair Value of Financial Instruments Under the Financial Account Standards Board Accounting Standards Codification (“FASB ASC”), we are permitted to elect to measure financial instruments and certain other items at fair value, with the change in fair value recorded in earnings. We elected not to measure any eligible items using the fair value option. Consistent with Fair Value Measurement Topic of the FASB ASC, we implemented guidelines relating to the disclosure of our methodology for periodic measurement of our assets and liabilities recorded at fair market value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three 1 3 ● Level 1, ● Level 2, ● Level 3, one Our Level 1 Stock-Based Compensation Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation Cash and Cash Equivalents The Company classifies investments as cash equivalents if the original maturity of an investment is three Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not overstated due to uncollectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one December 31, 2016 2015. 2016. Inventory Inventories are stated at the lower of cost or market. Cost is determined on a first first December 31, 2016 2015, $14,700 $0, Property and Equipment Property and equipment are stated on the basis of historical cost less accumulated depreciation. Depreciation is provided using the straight-line method over the two seven Patents and Patent Expenditures ABI holds patent license agreements and holds patents that are owned by the Company. All patent license agreements remain in effect over the life of the underlying patents. Accordingly, the patent license fee is being amortized over the estimated life of the patent using the straight-line method. Patent fees and legal fees associated with the issuance of new owned patents are capitalized and amortized over the estimated 15 20 may Long-lived Assets Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. No impairment losses have been recorded since inception. Income Taxes The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be realized. Research and Development Research and development costs are expensed as incurred. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Basic and Diluted Net Income ( Loss ) Per Share Net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding. For the year ended December 31, 2016 2015, Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist principally of cash. The Company has cash balances in a single financial institution which, from time to time, could exceed the federally insured limit of $250,000. Recent Accounting Pronouncements Management does not anticipate that any recently issued but not yet effective accounting pronouncements will materially impact the Company’s financial condition.

Note 2 - Property, Equipment an

Note 2 - Property, Equipment and Software, Net	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	2 . Property, Equipment and Software , net Property, equipment and software are stated at cost less accumulated depreciation and consist of the following at December 31, 2016 2015: 2016 2015 Furniture and equipment $ 92,988 $ 45,302 Software 8,012 8,012 101,000 53,314 Less: accumulated depreciation (56,786 ) (47,516 ) Property, equipment and software, net $ 44,214 $ 5,798 Depreciation expense amounted to $9,270 December 31, 2016 $1,283 December 31, 2015

Note 3 - Patents, Net

Note 3 - Patents, Net	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	3 . Patents, net Patents are stated at cost less accumulated amortization and consist of the following at December 31, 2016 2015: 2016 2015 Patents $ 289,228 $ 188,584 Less: accumulated amortization (133,165 ) (116,479 ) Patents, net $ 156,063 $ 72,105 Amortization expense amounted to $16,686 December 31, 2016 $18,489 December 31, 2015, Estimated future amortization expense is as follows: 2017 $ 16,807 2018 15,444 2019 9,793 2020 6,584 2021 4,379 Thereafter 103,056 Total expense $ 156,063

Note 4 - Notes Payable - Relate

Note 4 - Notes Payable - Related Party	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	4 . Notes Payable - Related Part y 2016 2015 Note payable – related party $ - $ 234,555 Note payable – related party - 150,000 - 384,555 Less: current portion - (384,555 ) Notes payable – related party, long term $ - $ - On November 20, 2014, $150,000, 13 0029795076). four (4) September 1, 2015, September 1, 2018, first September 1, 2015, $37,811 no Subsequent to consummation of the Plan, The Yang Group provided $234,555 June 30, 2016, two one .64% $.1875 $384,555 June 30, 2016. #13 0029795076) 3

Note 5 - Convertible Notes Paya

Note 5 - Convertible Notes Payable - Related Party	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Convertible Debt [Text Block]	5. Notes Payable – Related Party 2016 2015 Convertible Note payable – related party $ 144,426 $ - Convertible Note payable – related party 262,500 - Convertible Note payable – related party 384,555 - Convertible Notes payable – related party $ 791,481 $ - During the fiscal year ended December 31, 2016, $144,426 January 11, 2016, .75%, may $.168 On March 18, 2016, $262,500 2016 1 March 10, 2016). .65% $.1875 On June 30, 2016, $384,555 two Related Party. The Convertible Note is due on demand, is unsecured, bears interest at the Short-Term Applicable Federal Rate of .64% $.1875

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	6. Related Party Transactions On April 4, 2016, $75,000 January 18, 2016 March 18, 2016, On May 23, 2016, $3,000,681 ($91,968 may one (1%) December 31, 2016, $54,133 $37,835, $546 2016. During the year ended December 31, 2016, $17,929 Hidden Valley Herbs of Kentucky, which is owned and operated by ABI Director and Stockholder Paul Tibbits. On November 7, 2016, $124,833 January 13, 2017. In April 2016, $187,500 1,000,000 2016 2). December 31, 2016, On December 20, 2016, $25,000 $37,500. $12,500 $5,000. December 30, 2016 December 31, 2016. January 3, 2017. December 2016.

Note 7 - Common Stock

Note 7 - Common Stock	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7. The Company has 100,000,000 December 31, 2016, 26,226,782 (21,916,143) (4,310,639). On March 10, 2016, 5,000,000 2016 2) $.1875 $937,500). During the second 2016, $234,375 1,250,000 2016 2 5,000,000 $.1875 May 6, 2016. July 11, 2016, 1,250,000 On September 30, 2016, 2016 2 2016 2 10,000,000 $.1875 $1,875,000. one (1) fourth 2016, 521,333 $.1875 $97,750.

Note 8 - Preferred Stock

Note 8 - Preferred Stock	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Preferred Stock [Text Block]	8 . Preferred Stock The shareholders have authorized 10,000,000 No December 31, 2016 2015 At December 31, 2016, $34,279 11 October 31, 2013, November 20, 2014

Note 9 - Stock Option and Stock

Note 9 - Stock Option and Stock Plans	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9 . Stock Option and Stock Plans Stock Plans * Issue Date Range Total Shares Authorized Share s Issued Shares Remaining 2008 Stock Incentive Plan 5/23/08 – 10/11/11 600,000 463,420 136,580 * The Board of Directors has approved all stock, stock option and stock warrant issuances.

Note 10 - Stock Options and War

Note 10 - Stock Options and Warrants	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Stock Option And Warrants [Text Block]	10 . Stock Options and Warrants Stock Options: During 2016, no no Directors, officers and consultants did not 2016 2015, A summary of the Company's stock option activity and related information for the years ended December 31, 2016 2015 December 31, 2016 December 31, 2015 Options Price Options Price Outstanding Beg. of Year 8,568 $ 0.95 81,726 $0.76 - 1.235 Granted - - - - Cancelled/Expired (8,568 ) 0.95 (73,158 ) 0.76 - 1.235 Exercised - - - - Outstanding End of Year - $ - 8,568 $0.95 Exercisable End of Year - $ - 8,568 $0.95 Stock Warrant s: A summary of the Company's stock warrant activity and related information for the years ended December 31, 2016 2015 December 31, 2016 December 31, 2015 Warrants Price Warrants Price Outstanding Beg. of Year - $ - 52,632 $ 0.57 Granted - - - - Cancelled/Expired - - (52,632 ) 0.57 Exercised - - - - Outstanding End of Year - $ - - $ - Exercisable End of Year - $ - - $ -

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 1 . Income Taxes Income tax expense (benefit) attributable to income from continuing operations differed from the amounts computed by applying the U.S. Federal income tax of 34% December 31, 2016 December 31, 2015 Provision (benefit) at statutory rate $ 228,000 $ 177,000 Change in valuation allowance (228,000 ) (177,000 ) $ 0 $ 0 The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2016 2015, December 31, 2016 December 31, 2015 Deferred tax assets: Net operating loss carryforward $ 7,601,000 $ 7,373,000 Deferred tax assets 7,601,000 7,373,000 Deferred tax liabilities: - - Net deferred tax assets 7,601,000 7,373,000 Valuation allowance (7,601,000 ) (7,373,000 ) $ 0 $ 0 At December 31, 2016, $22,357,000 2016 2035. may difficult and directly dependent upon many factors outside of the Company’s control, including, but not limited to, changes in the legal and regulatory framework and the operational and corporate structure of ABI and shareholders, or sales or transfers of stock by or among shareholders. For example, if ABI has experienced a change of control as defined in the relevant provisions of the IRC, 2 2 See 26 382 382

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 2 . Commitments and Contingencies Lease commitment Our executive and administrative offices are located at 4134 1,800 June 30, 2017 $1,070 December 31, 2016 2015, $12,715 $13,585 The Company shares office space with ACTS Global Healthcare, Inc. in Taipei, Taiwan. The lease expires on October 31, 2018 $70,000 December 31, 2016 2015, $41,889 $0 Litigation The Company is not a party to any litigation and is not aware of any pending litigation or unasserted claims or assessments as of December 31, 2016. Officer Compensation On December 20, 2016, January 1, 2017, $90,000 $75,000 $65,000 $10,000 15 th 31 st first first April 3, 2017.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	1 3 . Subsequent Events In January 2017, 270,000 $.1875 $50,625. In January 2017, 164,792 $.2579 2016

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Going Concern Policy [Policy Text Block]	Going Concern These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved operating income, and its operations are funded primarily from debt and equity financings. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability. The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may may may
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Under the Financial Account Standards Board Accounting Standards Codification (“FASB ASC”), we are permitted to elect to measure financial instruments and certain other items at fair value, with the change in fair value recorded in earnings. We elected not to measure any eligible items using the fair value option. Consistent with Fair Value Measurement Topic of the FASB ASC, we implemented guidelines relating to the disclosure of our methodology for periodic measurement of our assets and liabilities recorded at fair market value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three 1 3 ● Level 1, ● Level 2, ● Level 3, one Our Level 1
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company classifies investments as cash equivalents if the original maturity of an investment is three
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not overstated due to uncollectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one December 31, 2016 2015. 2016.
Inventory, Policy [Policy Text Block]	Inventory Inventories are stated at the lower of cost or market. Cost is determined on a first first December 31, 2016 2015, $14,700 $0,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated on the basis of historical cost less accumulated depreciation. Depreciation is provided using the straight-line method over the two seven
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and Patent Expenditures ABI holds patent license agreements and holds patents that are owned by the Company. All patent license agreements remain in effect over the life of the underlying patents. Accordingly, the patent license fee is being amortized over the estimated life of the patent using the straight-line method. Patent fees and legal fees associated with the issuance of new owned patents are capitalized and amortized over the estimated 15 20 may
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-lived Assets Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. No impairment losses have been recorded since inception.
Income Tax, Policy [Policy Text Block]	Income Taxes The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be realized.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Income ( Loss ) Per Share Net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding. For the year ended December 31, 2016 2015,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist principally of cash. The Company has cash balances in a single financial institution which, from time to time, could exceed the federally insured limit of $250,000.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Management does not anticipate that any recently issued but not yet effective accounting pronouncements will materially impact the Company’s financial condition.

Note 2 - Property, Equipment 21

Note 2 - Property, Equipment and Software, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	2016 2015 Furniture and equipment $ 92,988 $ 45,302 Software 8,012 8,012 101,000 53,314 Less: accumulated depreciation (56,786 ) (47,516 ) Property, equipment and software, net $ 44,214 $ 5,798

Note 3 - Patents, Net (Tables)

Note 3 - Patents, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2016 2015 Patents $ 289,228 $ 188,584 Less: accumulated amortization (133,165 ) (116,479 ) Patents, net $ 156,063 $ 72,105
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2017 $ 16,807 2018 15,444 2019 9,793 2020 6,584 2021 4,379 Thereafter 103,056 Total expense $ 156,063

Note 4 - Notes Payable - Rela23

Note 4 - Notes Payable - Related Party (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	2016 2015 Note payable – related party $ - $ 234,555 Note payable – related party - 150,000 - 384,555 Less: current portion - (384,555 ) Notes payable – related party, long term $ - $ -

Note 5 - Convertible Notes Pa24

Note 5 - Convertible Notes Payable - Related Party (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Convertible Notes Payable, Related Parties [Table Text Block]	2016 2015 Convertible Note payable – related party $ 144,426 $ - Convertible Note payable – related party 262,500 - Convertible Note payable – related party 384,555 - Convertible Notes payable – related party $ 791,481 $ -

Note 9 - Stock Option and Sto25

Note 9 - Stock Option and Stock Plans (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock Plans * Issue Date Range Total Shares Authorized Share s Issued Shares Remaining 2008 Stock Incentive Plan 5/23/08 – 10/11/11 600,000 463,420 136,580

Note 10 - Stock Options and W26

Note 10 - Stock Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock Plans * Issue Date Range Total Shares Authorized Share s Issued Shares Remaining 2008 Stock Incentive Plan 5/23/08 – 10/11/11 600,000 463,420 136,580
Stock Warrant [Member]
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	December 31, 2016 December 31, 2015 Warrants Price Warrants Price Outstanding Beg. of Year - $ - 52,632 $ 0.57 Granted - - - - Cancelled/Expired - - (52,632 ) 0.57 Exercised - - - - Outstanding End of Year - $ - - $ - Exercisable End of Year - $ - - $ -
Employee Stock Option [Member]
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	December 31, 2016 December 31, 2015 Options Price Options Price Outstanding Beg. of Year 8,568 $ 0.95 81,726 $0.76 - 1.235 Granted - - - - Cancelled/Expired (8,568 ) 0.95 (73,158 ) 0.76 - 1.235 Exercised - - - - Outstanding End of Year - $ - 8,568 $0.95 Exercisable End of Year - $ - 8,568 $0.95

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	December 31, 2016 December 31, 2015 Provision (benefit) at statutory rate $ 228,000 $ 177,000 Change in valuation allowance (228,000 ) (177,000 ) $ 0 $ 0
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2016 December 31, 2015 Deferred tax assets: Net operating loss carryforward $ 7,601,000 $ 7,373,000 Deferred tax assets 7,601,000 7,373,000 Deferred tax liabilities: - - Net deferred tax assets 7,601,000 7,373,000 Valuation allowance (7,601,000 ) (7,373,000 ) $ 0 $ 0

Note 1 - Organization and Sum28

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Inventory, Net	$ 14,700	$ 0
Cash, FDIC Insured Amount	250,000
Accounts Receivable, Net	0	0
Allowance for Doubtful Accounts Receivable	0	$ 0
Provision for Doubtful Accounts	0
Patents [Member]
Impairment of Intangible Assets (Excluding Goodwill)	0
Impairment of Long-Lived Assets Held-for-use	$ 0
Minimum [Member]
Property, Plant and Equipment, Estimated Useful Lives	two
Minimum [Member] | Patents [Member]
Finite-Lived Intangible Asset, Useful Life	15 years
Maximum [Member]
Property, Plant and Equipment, Estimated Useful Lives	seven
Maximum [Member] | Patents [Member]
Finite-Lived Intangible Asset, Useful Life	20 years

Note 2 - Property, Equipment 29

Note 2 - Property, Equipment and Software, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Depreciation	$ 9,270	$ 1,283

Note 2 - Property, Equipment 30

Note 2 - Property, Equipment and Software, Net - Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, plant and equipment, gross	$ 101,000	$ 53,314
Less: accumulated depreciation	(56,786)	(47,516)
Property, equipment and software, net	44,214	5,798
Furniture and Fixtures [Member]
Property, plant and equipment, gross	92,988	45,302
Software and Software Development Costs [Member]
Property, plant and equipment, gross	$ 8,012	$ 8,012

Note 3 - Patents, Net (Details

Note 3 - Patents, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Amortization of Intangible Assets	$ 16,686	$ 18,489

Note 3 - Patents, Net - Patents

Note 3 - Patents, Net - Patents (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Patents	$ 156,063	$ 72,105
Patents, net	156,063
Patents [Member]
Patents	289,228	188,584
Less: accumulated amortization	(133,165)	(116,479)
Patents, net	$ 156,063	$ 72,105

Note 3 - Patents, Net - Estimat

Note 3 - Patents, Net - Estimated Future Amortization Expense (Details)	Dec. 31, 2016USD ($)
2,017	$ 16,807
2,018	15,444
2,019	9,793
2,020	6,584
2,021	4,379
Thereafter	103,056
Total expense	$ 156,063

Note 4 - Notes Payable - Rela34

Note 4 - Notes Payable - Related Party (Details Textual)	Apr. 04, 2016USD ($)	Sep. 01, 2015USD ($)	Nov. 21, 2014USD ($)	Nov. 20, 2014USD ($)	Mar. 18, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)	Jun. 30, 2016USD ($)$ / shares
Notes Payable, Related Parties							$ 384,555
Proceeds from Related Party Debt						187,500
Notes Payable, Convertible, Related Parties, Classified Current						791,481		791,481
Chief Executive Officer [Member]
Number of Installments				4
Debt Instrument, Periodic Payment		$ 37,811
Repayments of Related Party Debt	$ 75,000							0
Proceeds from Related Party Debt			$ 234,555		$ 75,000
Debt Instrument, Interest Rate, Stated Percentage									0.64%
Debt Instrument, Convertible, Conversion Price | $ / shares									$ 0.1875
Notes Payable, Convertible, Related Parties, Classified Current									$ 384,555
Chief Executive Officer [Member] | Secured Debt [Member]
Notes Payable, Related Parties				$ 150,000			$ 150,000

Note 4 - Notes Payable - Rela35

Note 4 - Notes Payable - Related Party - Related Party Transactions (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Nov. 20, 2014
Note payable – related party		$ 384,555
Less: current portion		(384,555)
Notes payable – related party, long term	0	0
Chief Executive Officer [Member] | Unsecured Debt [Member]
Note payable – related party		234,555
Chief Executive Officer [Member] | Secured Debt [Member]
Note payable – related party		$ 150,000	$ 150,000

Note 5 - Convertible Notes Pa36

Note 5 - Convertible Notes Payable - Related Party (Details Textual) - USD ($)	Dec. 31, 2016	Jun. 30, 2016	Mar. 18, 2016	Dec. 31, 2015
Notes Payable, Convertible, Related Parties, Classified Current	$ 791,481
Chief Executive Officer [Member]
Notes Payable, Convertible, Related Parties, Classified Current		$ 384,555
Debt Instrument, Interest Rate, Stated Percentage		0.64%
Debt Instrument, Convertible, Conversion Price		$ 0.1875
Chief Executive Officer [Member] | First Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current	$ 144,426
Debt Instrument, Interest Rate, Stated Percentage	0.75%
Debt Instrument, Convertible, Conversion Price	$ 0.168
Chief Executive Officer [Member] | Second Issuance [Member] | Private Placement Convertible Promissory Notes [Member]
Notes Payable, Convertible, Related Parties, Classified Current	$ 262,500		$ 262,500
Debt Instrument, Interest Rate, Stated Percentage			0.65%
Debt Instrument, Convertible, Conversion Price			$ 0.1875
Chief Executive Officer [Member] | Third Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current	$ 384,555	$ 384,555
Debt Instrument, Interest Rate, Stated Percentage		0.64%
Debt Instrument, Convertible, Conversion Price		$ 0.1875

Note 5 - Convertible Notes Pa37

Note 5 - Convertible Notes Payable - Related Party - Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2016	Jun. 30, 2016	Mar. 18, 2016	Dec. 31, 2015
Convertible note payable – related party	$ 791,481
Chief Executive Officer [Member]
Convertible note payable – related party		$ 384,555
Chief Executive Officer [Member] | First Issuance [Member]
Convertible note payable – related party	144,426
Chief Executive Officer [Member] | Second Issuance [Member] | Private Placement Convertible Promissory Notes [Member]
Convertible note payable – related party	262,500		$ 262,500
Chief Executive Officer [Member] | Third Issuance [Member]
Convertible note payable – related party	$ 384,555	$ 384,555

Note 6 - Related Party Transa38

Note 6 - Related Party Transactions (Details Textual)	Dec. 20, 2016USD ($)	Nov. 07, 2016USD ($)	May 23, 2016USD ($)	May 23, 2016TWD	Apr. 04, 2016USD ($)	Nov. 21, 2014USD ($)	Apr. 30, 2016USD ($)shares	Mar. 18, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)
Proceeds from Related Party Debt									$ 187,500
Allocated Share-based Compensation Expense									0
Chief Executive Officer [Member]
Proceeds from Related Party Debt						$ 234,555		$ 75,000
Repayments of Related Party Debt					$ 75,000						$ 0
Allocated Share-based Compensation Expense	$ 37,500
Chief Executive Officer [Member] | Cash Bonus [Member]
Officers' Compensation	25,000
ACTS Global Healthcare, Inc. [Member]
Payments for Advance to Affiliate			$ 91,968	TWD 3,000,681
Percentage to be Paid to Affiliate for Services Rendered			1.00%	1.00%
Prepaid Expense, Current									37,835		$ 37,835
Agency Fee									546
ACTS Global Healthcare, Inc. [Member] | Expenditures by ACTS Global [Member]
Related Party Transaction, Amounts of Transaction									54,133
Hidden Valley Herbs of Kentucky [Member] | Ginseng [Member]
Related Party Transaction, Purchases from Related Party									$ 17,929
Investor Related to Amarillo Biosciences (Hong Kong) Ltd. [Member] | Medical Equipment [Member]
Proceeds from Deposits from Customers		$ 124,833
Investor Related to Amarillo Biosciences (Hong Kong) Ltd. [Member] | Proceeds Received In Exchange for Potential Issuance of Common Stock [Member]
Related Party Transaction, Amounts of Transaction							$ 187,500
Investor Related to Amarillo Biosciences (Hong Kong) Ltd. [Member] | Potentially Issuable Common Stock For Cash [Member]
Stock Issuable Upon Receipt of Private Placement Memorandum | shares							1,000,000
Chief Financial Officer [Member]
Allocated Share-based Compensation Expense	5,000
Chief Financial Officer [Member] | Cash Bonus [Member]
Officers' Compensation	$ 12,500

Note 7 - Common Stock (Details

Note 7 - Common Stock (Details Textual) - USD ($)	Jul. 11, 2016	Mar. 10, 2016	Dec. 31, 2016	Jun. 30, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Common Stock, Shares Authorized			100,000,000			100,000,000	100,000,000
Common Stock, Shares Outstanding and Reserved			26,226,782			26,226,782
Common Stock, Shares, Outstanding			21,916,143			21,916,143	20,144,810
Shares Authorized During Period, Private Placement				1,250,000
Amount of Private Placement		$ 937,500			$ 1,875,000
Proceeds from Issuance of Private Placement				$ 234,375		$ 332,125
Private Placement [Member]
Sale of Stock, Price Per Share		$ 0.1875		$ 0.1875
Proceeds from Issuance of Private Placement			$ 97,750
Stock Issued During Period, Shares, New Issues	1,250,000		521,333
Share Price					$ 0.1875
Shares Issued, Price Per Share			$ 0.1875			$ 0.1875
Maximum [Member]
Shares Authorized During Period, Private Placement		5,000,000			10,000,000
Debt Convertible to Common Stock [Member]
Common Stock, Capital Shares Reserved for Future Issuance			4,310,639			4,310,639

Note 8 - Preferred Stock (Detai

Note 8 - Preferred Stock (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Amount of Preferred Dividends in Arrears	$ 34,279
Preferred Stock, Shares Outstanding	0	0

Note 9 - Stock Option and Sto41

Note 9 - Stock Option and Stock Plans - Stock Option Plan Summary (Details) - 2008 Stock Incentive Plan [Member]	12 Months Ended
	Dec. 31, 2016shares	[1]
Total Shares Authorized (in shares)	600,000
Shares Issued (in shares)	463,420
Shares Remaining (in shares)	136,580
[1]	The Board of Directors has approved all stock, stock option and stock warrant issuances.

Note 10 - Stock Options and W42

Note 10 - Stock Options and Warrants (Details Textual) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0
Allocated Share-based Compensation Expense	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	0

Note 10 - Stock Options and W43

Note 10 - Stock Options and Warrants - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Outstanding Beg. of Year, Shares (in shares)	8,568	81,726
Outstanding Beg. of Year, Price (in dollars per share)	$ 0.95
Cancelled/Expired, Shares (in shares)	(8,568)	(73,158)
Cancelled/Expired, Price (in dollars per share)	$ 0.95
Outstanding End of Year, Shares (in shares)		8,568
Outstanding End of Year, Price (in dollars per share)		$ 0.95
Exercisable End of Year, Shares (in shares)		8,568
Exercisable End of Year, Price (in dollars per share)		$ 0.95
Minimum [Member]
Outstanding Beg. of Year, Price (in dollars per share)		0.76
Cancelled/Expired, Price (in dollars per share)		0.76
Maximum [Member]
Outstanding Beg. of Year, Price (in dollars per share)		1.235
Cancelled/Expired, Price (in dollars per share)		$ 1.235

Note 10 - Stock Options and W44

Note 10 - Stock Options and Warrants - Stock Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Outstanding Beg. of Year, Warrants (in shares)		52,632
Outstanding Beg. of Year, Warrants Price (in dollars per share)		$ 0.57
Granted, Warrants (in shares)
Granted, Warrants Price (in dollars per share)
Cancelled/Expired, Warrants (in shares)		(52,632)
Cancelled/Expired, Warrants Price (in dollars per share)		$ 0.57
Exercised, Warrants Price (in dollars per share)
Outstanding End of Year, Warrants (in shares)
Outstanding End of Year, Warrants Price (in dollars per share)
Exercisable End of Year, Warrants (in shares)
Exercisable End of Year, Warrants Price (in dollars per share)

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual)	12 Months Ended
	Dec. 31, 2016USD ($)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%
Operating Loss Carryforwards	$ 22,357,000

Note 11 - Income Taxes - Income

Note 11 - Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Provision (benefit) at statutory rate	$ 228,000	$ 177,000
Change in valuation allowance	(228,000)	(177,000)
	$ 0	$ 0

Note 11 - Income Taxes - Deferr

Note 11 - Income Taxes - Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Net operating loss carryforward	$ 7,601,000	$ 7,373,000
Deferred tax assets	7,601,000	7,373,000
Deferred tax liabilities:
Net deferred tax assets	7,601,000	7,373,000
Valuation allowance	(7,601,000)	(7,373,000)
	$ 0	$ 0

Note 12 - Commitments and Con48

Note 12 - Commitments and Contingencies (Details Textual)	Dec. 20, 2016USD ($)	Dec. 31, 2016USD ($)ft²	Dec. 31, 2015USD ($)
Chief Executive Officer [Member]
Officer Compensation, Annual Compensation, Cash	$ 90,000
Officer Compensation, Annual Compensation, Share Value	75,000
Chief Financial Officer [Member]
Officer Compensation, Annual Compensation, Cash	65,000
Officer Compensation, Annual Compensation, Share Value	$ 10,000
Executive and Administrative Offices [Member]
Area of Real Estate Property | ft²		1,800
Operating Leases Rent Expense Monthly Amount		$ 1,070
Operating Leases, Rent Expense		12,715	$ 13,585
Shared Office Space with ACTS Global Healthcare, Inc. in Taipei, Taiwan [Member]
Operating Leases Rent Expense Monthly Amount		70,000
Operating Leases, Rent Expense		$ 41,889	$ 0

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - Subsequent Event [Member]	1 Months Ended
	Jan. 31, 2017USD ($)$ / sharesshares
Stock Issued During Period, Shares, New Issues | shares	270,000
Shares Issued, Price Per Share | $ / shares	$ 0.1875
Proceeds from Issuance of Common Stock | $	$ 50,625
CEO and CFO [Member]
Shares Issued, Price Per Share | $ / shares	$ 0.2579
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	164,792